Cathrin E Hansen, Alwin Kamermans, Kevin Mol, Kristina Berve, Carla Rodriguez-Mogeda, Wing Ka Fung, Bert van Het Hof, Ruud D Fontijn, Susanne M A van der Pol, Laura Michalick, Wolfgang M Kuebler, Boyd Kenkhuis, Willeke van Roon-Mom, Wolfgang Liedtke, Britta Engelhardt, Gijs Kooij, Maarten E Witte, Helga E de Vries
BACKGROUND: Blood-brain barrier (BBB) dysfunction and immune cell migration into the central nervous system (CNS) are pathogenic drivers of multiple sclerosis (MS). Ways to reinstate BBB function and subsequently limit neuroinflammation present promising strategies to restrict disease progression. However, to date, the molecular players directing BBB impairment in MS remain poorly understood. One suggested candidate to impact BBB function is the transient receptor potential vanilloid-type 4 ion channel (TRPV4), but its specific role in MS pathogenesis remains unclear...
March 23, 2024: Journal of Neuroinflammation